title: [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
abstract: Using high performance liquid chromatography and radioimmunoassay we have investigated the stability of prostaglandin (PG) E1 and its metabolite 13,14-dihydro-PGE1 in human plasma as well as the initial metabolism of PGE1 infused intravenously (80 micrograms/patient/hour) in patients with peripheral arterial occlusive disease. 13,14-dihydro-PGE1 degraded like PGE1 in human plasma at 37 degrees C with a half-life of several hours. During infusion of PGE1 higher plasma concentrations of the major metabolite 15-keto-13,14-dihydro-PGE1 and lower plasma levels of PGE1 and 13,14-dihydro-PGE1 were observed. The metabolite 13,14-dihydro-PGE1 is of interest, since in contrast to 15-keto-13,14-dihydro-PGE1 it is biologically active. The biosynthesis of 13,14-dihydro-PGE1 could contribute to the therapeutic efficacy of PGE1 administered intravenously in patients with peripheral arterial occlusive disease.
authors.affiliation: Institut für Pharmakologie und Toxikologie, Ruhr-Universität Bochum, Bundesrepublik Deutschland.
authors.forename: W H
authors.initials: WH
authors.lastname: Hesse
authors.forename: G
authors.initials: G
authors.lastname: Rudofsky
authors.forename: B A
authors.initials: BA
authors.lastname: Peskar
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000527:Alprostadil / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D001157:Arterial Occlusive Diseases / Q000097:blood* / Q000628:therapy*; D001711:Biotransformation; D015232:Dinoprostone / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged
chemical_list: C069881:13,14-dihydroprostaglandin E1; C025087:15-keto-13,14-dihydroprostaglandin E2; D000527:Alprostadil; D015232:Dinoprostone
vernacular_title: Metabolismus von intravenös appliziertem Prostaglandin E1 bei Patienten mit peripherer arterieller Verschlusskrankheit.